CDK4 and Thrombocytopenia: In addition, Kassem et al. reported a study that in the CDK4/6 inhibitors arm, the incidence of all-grade leukopenia ranged from 20.8 to 45.5% and all-grade thrombocytopenia from 9 to 36.2% [26].